Companies Arcus Biosciences, Inc.
Arcus Biosciences (RCUS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Arcus Biosciences, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers82nd pct.Of 17 peer CEOs
CEO pay, last three years
- $10,120,945FY2023
- $7,279,504FY2024
- $9,656,813FY2025
CEO total pay was $9,656,813 in fiscal 2025, up from $7,279,504 in fiscal 2024.
FY2025: salary $775,000 · bonus $0 · stock awards $2,199,450 · option awards $6,008,860
Executives and directors
Jennifer Jarrett · COORichard Markus · Chief Medical OfficerJuan Carlos Jaen · PresidentRobert Goeltz · CFOTerry Rosen · CEOAndrew Perlman, M.D., Ph.D · Independent DirectorAntoni Ribas, M.D., Ph.D · Independent DirectorDavid Lacey, M.D · Independent DirectorDietmar Berger, M.D., Ph.D · DirectorJohanna Mercier · DirectorKathryn Falberg · Independent DirectorLinda Higgins, Ph.D · DirectorNicole Lambert · Independent DirectorPatrick Machado, J.D · Independent DirectorYasunori Kaneko, M.D · Lead Independent Director
Frequently asked questions
Who was the highest-paid executive at Arcus Biosciences, Inc. in fiscal 2025?
As disclosed, Terry Rosen (Chief Executive Officer and Director) was the highest-paid executive at Arcus Biosciences, Inc. in fiscal 2025, with total compensation of $9,656,813.
How does Arcus Biosciences, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Terry Rosen's total compensation ranked at the 82nd percentile of Arcus Biosciences, Inc.'s disclosed peer group.
What is Arcus Biosciences, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Arcus Biosciences, Inc.'s CEO-to-median employee pay ratio was 35.9:1.
How did shareholders vote on Arcus Biosciences, Inc.'s executive compensation?
As disclosed, 91.04% of shareholders supported Arcus Biosciences, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Arcus Biosciences, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Arcus Biosciences, Inc. reported total board compensation of $1,485,168 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Terry Rosen | $775,000 | $0 | $2,199,450 | $6,008,860 | $658,750 | $0 | $14,753 | $9,656,813 |
| Chief Executive Officer and Director | ||||||||
| Richard Markus | 552,307 | 100,000 | 936,153 | 2,636,263 | 270,000 | 0 | 11,576 | 4,506,299 |
| Chief Medical Officer | ||||||||
| Juan Carlos Jaen | 660,000 | 0 | 666,500 | 1,848,880 | 330,000 | 0 | 15,544 | 3,520,924 |
| President | ||||||||
| Jennifer Jarrett | 660,000 | 0 | 666,500 | 1,848,880 | 330,000 | 0 | 10,819 | 3,516,199 |
| Chief Operating Officer | ||||||||
| Robert Goeltz | 540,000 | 0 | 493,210 | 1,386,660 | 243,000 | 0 | 9,694 | 2,672,564 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Terry Rosen | $9,656,813 | $7,279,504 | $10,120,945 | ↑ +2,377,309 |
| Richard Markus | 4,506,299 | — | — | — |
| Juan Carlos Jaen | 3,520,924 | 3,324,960 | 4,750,398 | ↑ +195,964 |
| Jennifer Jarrett | 3,516,199 | 3,319,110 | 4,744,548 | ↑ +197,089 |
| Robert Goeltz | 2,672,564 | 2,023,065 | 3,587,832 | ↑ +649,499 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The goals of our executive compensation program are to align our executive officers compensation with our corporate objectives and the interests of our stockholders. To do this, we focus on the following principles to guide decisions regarding executive compensation: Competitive Total Compensation Package, Pay-for-Performance, Alignment with Stockholders, Flexibility, Simplicity and Parity, Avoidance of Excessive Perquisites.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jennifer Jarrett | RSU | 2025-01-23 | — | — | 50,000 | — | $666,500 |
| Terry Rosen | RSU | 2025-01-23 | — | — | 165,000 | — | 2,199,450 |
| Richard Markus | RSU | 2025-02-10 | — | — | 75,193 | — | 936,153 |
| Robert Goeltz | OPTION | 2025-01-23 | — | — | 150,000 | — | 1,386,660 |
| Jennifer Jarrett | OPTION | 2025-01-23 | — | — | 200,000 | — | 1,848,880 |
| Robert Goeltz | RSU | 2025-01-23 | — | — | 37,000 | — | 493,210 |
| Terry Rosen | OPTION | 2025-01-23 | — | — | 650,000 | — | 6,008,860 |
| Juan Carlos Jaen | OPTION | 2025-01-23 | — | — | 200,000 | — | 1,848,880 |
| Juan Carlos Jaen | RSU | 2025-01-23 | — | — | 50,000 | — | 666,500 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jennifer Jarrett | $666,500 | $0 | $1,848,880 | 0.0% |
| Terry Rosen | 2,199,450 | 0 | 6,008,860 | 0.0% |
| Richard Markus | 936,153 | 0 | 0 | 0.0% |
| Robert Goeltz | 493,210 | 0 | 1,386,660 | 0.0% |
| Juan Carlos Jaen | 666,500 | 0 | 1,848,880 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Goeltz | Option | 1,302 | 33.03 | — |
| Juan Carlos Jaen | Option | 2,604 | 33.03 | — |
| Jennifer Jarrett | Option | 2,604 | 33.03 | — |
| Terry Rosen | Option | 4,255 | 33.03 | — |
| Robert Goeltz | RSU | 8,500 | — | 202,555 |
| Robert Goeltz | RSU | 11,000 | — | 262,130 |
| Juan Carlos Jaen | RSU | 11,450 | — | 272,854 |
| Jennifer Jarrett | RSU | 11,450 | — | 272,854 |
| Juan Carlos Jaen | RSU | 20,000 | — | 476,600 |
| Jennifer Jarrett | RSU | 20,000 | — | 476,600 |
| Terry Rosen | RSU | 26,425 | — | 629,708 |
| Robert Goeltz | RSU | 27,750 | — | 661,283 |
| Robert Goeltz | Option | 37,429 | 22.02 | — |
| Juan Carlos Jaen | RSU | 37,500 | — | 893,625 |
| Jennifer Jarrett | RSU | 37,500 | — | 893,625 |
| Robert Goeltz | Option | 45,104 | 15.44 | — |
| Terry Rosen | RSU | 50,000 | — | 1,191,500 |
| Juan Carlos Jaen | Option | 50,348 | 22.02 | — |
| Jennifer Jarrett | Option | 50,348 | 22.02 | — |
| Richard Markus | RSU | 56,394 | — | 1,343,869 |
| Juan Carlos Jaen | Option | 84,583 | 15.44 | — |
| Jennifer Jarrett | Option | 84,583 | 15.44 | — |
| Robert Goeltz | Option | 115,625 | 13.33 | — |
| Terry Rosen | Option | 116,187 | 22.02 | — |
| Terry Rosen | RSU | 123,750 | — | 2,948,963 |
| Juan Carlos Jaen | Option | 154,167 | 13.33 | — |
| Jennifer Jarrett | Option | 154,167 | 13.33 | — |
| Terry Rosen | Option | 211,406 | 15.44 | — |
| Richard Markus | Option | 235,357 | 12.45 | — |
| Terry Rosen | Option | 501,042 | 13.33 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David Lacey, M.DIndependent · Compensation · Nominating/Governance (Chair) · Science | $87,788 | $133,266 | $312,710 | $0 | $30,000 | $563,764 |
| Antoni Ribas, M.D., Ph.DIndependent · Science | 55,288 | 133,266 | 312,710 | 0 | 20,000 | 521,264 |
| Yasunori Kaneko, M.DIndependent · Lead Independent Director · Audit · Compensation (Chair) | 100,577 | 133,266 | 266,488 | 0 | 0 | 500,331 |
| Andrew Perlman, M.D., Ph.DIndependent · Audit · Science (Chair) | 72,788 | 133,266 | 266,488 | 0 | 0 | 472,542 |
| Kathryn FalbergIndependent · Audit (Chair) · Compensation | 69,080 | 133,266 | 266,488 | 0 | 0 | 468,834 |
| Nicole LambertIndependent · Compensation · Nominating/Governance | 61,497 | 133,266 | 266,488 | 0 | 0 | 461,251 |
| Patrick Machado, J.DIndependent · Nominating/Governance | 55,288 | 133,266 | 266,488 | 0 | 0 | 455,042 |
| Terry Rosen, Ph.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Johanna MercierNot independent | 0 | 0 | 0 | 0 | 0 | 0 |
| Linda Higgins, Ph.DNot independent · Science | 0 | 0 | 0 | 0 | 0 | 0 |
| Dietmar Berger, M.D., Ph.DNot independent · Science · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $502,306 |
| Equity awards (grant-date value) | $932,862 |
| All other compensation | $50,000 |
| Total cost of the board | $1,485,168 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Arcus Biosciences as a peer
Companies that benchmark against RCUS
30 companies name RCUS as a compensation peer
- AGIOS PHARMACEUTICALS, INC.AGIOFY2025
- ARROWHEAD PHARMACEUTICALS, INC.ARWRFY2025
- ARVINAS, INC.ARVNFY2025
- BICYCLE THERAPEUTICS PLCBCYCFY2024
- CG Oncology, Inc.CGONFY2025
- Cogent Biosciences, Inc.COGTFY2025
- Denali Therapeutics Inc.DNLIFY2025
- Edgewise Therapeutics, Inc.EWTXFY2025
- ImmunityBio, Inc.IBRXFY2025
- Immunocore Holdings plcIMCRFY2025
- Janux Therapeutics, Inc.JANXFY2025
- Kura Oncology, Inc.KURAFY2025
- MACROGENICS INCMGNXFY2025
- Merus N.V.MRUSFY2024
- NEKTAR THERAPEUTICSNKTRFY2025
- Nurix Therapeutics, Inc.NRIXFY2025
- Olema Pharmaceuticals, Inc.OLMAFY2025
- OMEROS CORPOMERFY2025
- Phathom Pharmaceuticals, Inc.PHATFY2025
- PROTHENA CORP PUBLIC LTD COPRTAFY2025
- Relay Therapeutics, Inc.RLAYFY2025
- Scholar Rock Holding CorpSRRKFY2025
- SOLENO THERAPEUTICS INCSLNOFY2025
- SpringWorks Therapeutics, Inc.SWTXFY2024
- SUTRO BIOPHARMA, INC.STROFY2025
- Syndax Pharmaceuticals IncSNDXFY2025
- UroGen Pharma Ltd.URGNFY2025
- Xencor IncXNCRFY2025
- Y-mAbs Therapeutics, Inc.YMABFY2024
- Zymeworks Inc.ZYMEFY2025
Each company listed discloses RCUS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RCUS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
DAWN Day One Biopharmaceuticals, Inc.NTLA Intellia Therapeutics Inc.IOVA Iovance Biotherapeutics, Inc.PRTA Prothena Corporation PlcRGNX REGENXBIO Inc.SWTX SpringWorks Therapeutics, Inc.SNDX Syndax Pharmaceuticals Inc.IBRX ImmunityBio, Inc.ARWR Arrowhead Pharmaceuticals, Inc.DNLI Denali Therapeutics Inc.EDIT Editas Medicine, Inc.XNCR Xencor Inc.ALLO Allogene Therapeutics, Inc.KURA Kura Oncology, Inc.BBIO BridgeBio Pharma, Inc.ARVN Arvinas, Inc.ALEC Alector, Inc.
Peer reciprocity
The companies Arcus Biosciences, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Prothena Corporation Plc (PRTA)79SpringWorks Therapeutics, Inc. (SWTX)80Syndax Pharmaceuticals Inc. (SNDX)81ImmunityBio, Inc. (IBRX)82Arrowhead Pharmaceuticals, Inc. (ARWR)83Denali Therapeutics Inc. (DNLI)84Xencor Inc. (XNCR)85Kura Oncology, Inc. (KURA)86Arvinas, Inc. (ARVN)87
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | $760,000 | $7,899,760 | $6,689,100 | $798,000 | $16,153,317 |
| 2 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 3 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 4 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 5 | Day One Biopharmaceuticals, Inc. | 2025 | Jeremy Bender | 750,000 | 2,219,690 | 5,614,411 | 536,250 | 9,134,351 |
| 6 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 7 | Syndax Pharmaceuticals Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 8 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 9 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 10 | Prothena Corporation Plc | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 11 | Xencor Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 12 | Intellia Therapeutics Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 13 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 14 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 15 | Regenxbio Inc. | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 16 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 17 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 18 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Day One Biopharmaceuticals, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Alpine Rewards, LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Editas Medicine, Inc. | 91% | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| ImmunityBio, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Intellia Therapeutics Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Prothena Corporation Plc | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Regenxbio Inc. | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Syndax Pharmaceuticals Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Xencor Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 94,920,421 | 9,337,368 | 29,741 | 91.04% | Passed |
| 2025 | 2025-06-10 | 84,812,809 | 5,446,383 | 54,507 | 93.97% | Passed |
| 2024 | 2024-06-06 | 74,230,276 | 2,863,260 | 42,662 | 96.29% | Passed |
| 2023 | 2023-06-15 | 56,058,305 | 2,350,776 | 50,777 | 95.98% | Passed |
| 2022 | 2022-06-14 | 50,519,602 | 1,535,704 | 26,140 | 97.05% | Passed |
| 2021 | 2021-06-03 | 49,380,164 | 3,932,105 | 11,237 | 92.62% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | 91.04%a |
| 2025 | 2025-06-10 | 93.97%b |
| 2024 | 2024-06-06 | 96.29%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 35.9 : 1 |
|---|---|
| CEO total compensation | $9,656,813 |
| Median employee compensation | $269,269 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robert Goeltz | Chief Financial Officer | 2026-05-11 | D | 7,763 | $26 | $198,966 | Common | Form 4 ↗ |
| Alexander Azoy | Chief Accounting Officer | 2026-06-01 | D | 2,562 | 26 | 66,024 | Common | Form 4 ↗ |
| Carolyn C. Tang | General Counsel | 2026-06-11 | D | 34,090 | 3 | 87,748 | Derivative, Class A Common | Form 4 ↗ |
| Carolyn C. Tang | General Counsel | 2026-06-11 | A | 34,090 | 3 | 87,748 | Common | Form 4 ↗ |
| David L. Lacey | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Falberg | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Antoni Ribas | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Lacey | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Nicole Lambert | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nicole Lambert | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Kathryn Falberg | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Yasunori Kaneko | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew J. Perlman | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Antoni Ribas | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Andrew J. Perlman | Director | 2026-06-11 | A | 5,700 | 0 | 0 | Common | Form 4 ↗ |
| Yasunori Kaneko | Director | 2026-06-11 | A | 16,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-06-22 | D | 9,236 | 27 | 249,661 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-06-23 | D | 14,067 | 28 | 389,480 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-06-23 | D | 1,697 | 28 | 47,620 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-06-24 | D | 6,431 | 30 | 190,740 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-07-09 | D | 48,502 | 30 | 1,457,631 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-07-10 | D | 268 | 29 | 7,878 | Common | Form 4 ↗ |
| Juan Carlos Jaen | President | 2026-07-10 | D | 19,799 | 29 | 566,410 | Common | Form 4 ↗ |
| Alexander Azoy | Chief Accounting Officer | 2026-08-21 | D | 2,827 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alexander Azoy | Chief Accounting Officer | 2026-08-21 | A | 2,827 | 15 | 43,649 | Common | Form 4 ↗ |
| Alexander Azoy | Chief Accounting Officer | 2026-08-21 | D | 2,827 | 30 | 84,810 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (87 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Terry Rosen. DEF 14A, filed 2026-04-21. Section “Summary Compensation Table” · page 28. As printed: 9,656,813. View filing ↗
- Section 01, Richard Markus. DEF 14A, filed 2026-04-21. Section “Summary Compensation Table” · page 28. As printed: 4,506,299. View filing ↗
- Section 01, Juan Carlos Jaen. DEF 14A, filed 2026-04-21. Section “Summary Compensation Table” · page 28. As printed: 3,520,924. View filing ↗
- Section 01, Jennifer Jarrett. DEF 14A, filed 2026-04-21. Section “Summary Compensation Table” · page 28. As printed: 3,516,199. View filing ↗
- Section 01, Robert Goeltz. DEF 14A, filed 2026-04-21. Section “Summary Compensation Table” · page 28. As printed: 2,672,564. View filing ↗
- Section 03, Jennifer Jarrett RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Terry Rosen RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Markus RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Goeltz OPTION. DEF 14A, filed 2026-04-21. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jennifer Jarrett OPTION. DEF 14A, filed 2026-04-21. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Goeltz RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Terry Rosen OPTION. DEF 14A, filed 2026-04-21. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Juan Carlos Jaen OPTION. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Juan Carlos Jaen RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-21. Section “CEO Pay Ratio”. As printed: 35.9 : 1. View filing ↗
- Section 08, David Lacey, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 563,764. View filing ↗
- Section 08, Antoni Ribas, M.D., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 521,264. View filing ↗
- Section 08, Yasunori Kaneko, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 500,331. View filing ↗
- Section 08, Andrew Perlman, M.D., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 472,542. View filing ↗
- Section 08, Kathryn Falberg. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 468,834. View filing ↗
- Section 08, Nicole Lambert. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 461,251. View filing ↗
- Section 08, Patrick Machado, J.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 455,042. View filing ↗
- Section 08, Terry Rosen, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Johanna Mercier. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Linda Higgins, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Dietmar Berger, M.D., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Robert Goeltz 2026-05-11. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Azoy 2026-06-01. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carolyn C. Tang 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carolyn C. Tang 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David L. Lacey 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Falberg 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antoni Ribas 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David L. Lacey 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Lambert 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Lambert 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Falberg 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yasunori Kaneko 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew J. Perlman 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antoni Ribas 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew J. Perlman 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yasunori Kaneko 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-06-24. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-07-09. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-07-10. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Carlos Jaen 2026-07-10. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Azoy 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Azoy 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Azoy 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 91.04% (votes for as printed: 94,920,421). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 93.97% (votes for as printed: 84,812,809). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 96.29% (votes for as printed: 74,230,276). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 502,306 + equity 932,862 + all other 50,000 = 1,485,168, summed across the director compensation table rows.
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. View filing ↗
- ImmunityBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
- Arcus Biosciences, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Day One Biopharmaceuticals, Inc., Section 10b CEO total. 10-K/A, filed 2026-04-17. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 9,134,351. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Syndax Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Prothena Corporation Plc, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Prothena Corporation Plc's own proxy. As printed: 5,896,045. View filing ↗
- Xencor Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Intellia Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics Inc.'s own proxy. As printed: 5,063,899. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Regenxbio Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Regenxbio Inc.'s own proxy. As printed: 4,200,712. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
- Section 10a, Prothena Corporation Plc reciprocity. DEF 14A. Prothena Corporation Plc names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, SpringWorks Therapeutics, Inc. reciprocity. DEF 14A. SpringWorks Therapeutics, Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Syndax Pharmaceuticals Inc. reciprocity. DEF 14A. Syndax Pharmaceuticals Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ImmunityBio, Inc. reciprocity. DEF 14A. ImmunityBio, Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocity. DEF 14A. Arrowhead Pharmaceuticals, Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Denali Therapeutics Inc. reciprocity. DEF 14A. Denali Therapeutics Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Xencor Inc. reciprocity. DEF 14A. Xencor Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Kura Oncology, Inc. reciprocity. DEF 14A. Kura Oncology, Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Arvinas, Inc. reciprocity. DEF 14A. Arvinas, Inc. names Arcus Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗